MAPT and Alzheimer disease: Clinical studies have revealed that AD patients exhibit reduced insulin levels and expression of the insulin receptor in the brain, as well as insulin resistance [107], all of which can trigger Aβ accumulation, tau phosphorylation, neurodegeneration and cerebral glucose metabolism impairment, and cognitive decline [108].